Key result
Concomitant use of proton pump inhibitors with clopidogrel following coronary stenting did not increase the risk of all-cause death or myocardial infarction (4.6% vs 4.6%, P=0.77).
Why the study?
Does the addition of proton pump inhibitors to clopidogrel increase cardiovascular events or reduce gastrointestinal bleeding in Japanese patients following coronary stenting?
Cohort (n=1,887)
Does the addition of proton pump inhibitors to clopidogrel increase cardiovascular events or reduce gastrointestinal bleeding in Japanese patients following coronary stenting?
Absolute Event Rate: 4.6% vs 4.6%
p-value: p=0.77
Concomitant use of PPIs with clopidogrel after coronary stenting in Japanese patients does not increase cardiovascular risk and significantly reduces gastrointestinal bleeding.
No takes yet. Share an insight, caveat, or question.
PPI co-use with clopidogrel after stenting was not linked to higher CV events in this Japanese cohort; leaves open broader safety and GI benefit confirmation.
Aihara et al. (2012) conducted a cohort in Patients treated with clopidogrel following coronary stenting (n=1,887). Proton pump inhibitors (PPIs) vs. Treatment without PPI was evaluated on Composite of all-cause death or myocardial infarction (p=0.77). Concomitant use of proton pump inhibitors with clopidogrel following coronary stenting did not increase the risk of all-cause death or myocardial infarction (4.6% vs 4.6%, P=0.77).